Clinical Trial Update: Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain [Phase 3]

View source ↗

Summary

Phase 3 trial update on long-term safety of Sativex Oromucosal Spray as adjunctive therapy for uncontrolled persistent cancer-related pain; completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Pain

Drugs mentioned

• Sativex Oromucosal Spray (nabiximols)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Pain, Advanced Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-04-23